Carfilzomib, a proteasome inhibitor, is present in Carfimib 60 mg Injection 1's. It suppresses proteasomes, preventing protein breakdown in MM (multiple myeloma) cells. When proteasome function is stopped within the MM cell, a protein build-up occurs within the MM cell, which destroys the malignant cells.

FAQs

How does Carfimib 60 mg Injection 1's work?

Carfimib 60 mg Injection 1's contains Carfilzomib, which inhibits proteasomes and thereby prevents protein breakdown in MM (multiple myeloma) cells. When the proteasome action within the MM cell is disturbed, a protein accumulation occurs, destroying the cancerous cells.

Is it safe to father a child while taking Carfimib 60 mg Injection 1's?

No, it is unsafe to father a child while taking Carfimib 60 mg Injection 1's. It is recommended for sexually active men to use condoms while on treatment and for at least several months after their last dose of Carfimib 60 mg Injection 1's.

Is Carfimib 60 mg Injection 1's combines with other medications to treat multiple myeloma?

Based on the medical condition, Carfimib 60 mg Injection 1's may be given alone or together with other medicines used to treat multiple myeloma.

What should I do if I experience Infusion-related reactions?

Tell your healthcare professional immediately if you get any signs of an infusion-related reaction during or after the infusion. Your doctor may give other medicines, or the infusion may need to be slowed down or stopped.

Carfimib 60 mg Injection 1's causes a drop in blood cell count?

Carfimib 60 mg Injection 1's can cause a significant decrease in the number of blood cells and platelets. Your doctor may suggest laboratory tests before and during the treatment. Tell your healthcare provider if you develop a fever or have signs of bruising or bleeding.